Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands |
1 Months Ended | 3 Months Ended | |||
|---|---|---|---|---|---|
Apr. 30, 2026 |
Mar. 31, 2026 |
Mar. 31, 2026 |
May 13, 2026 |
Oct. 31, 2025 |
|
| Subsequent Events | |||||
| Payments of debt issuance costs | $ 474 | ||||
| InnoCare Pharma Inc | |||||
| Subsequent Events | |||||
| Regulatory milestones payable | $ 20,000 | ||||
| Follow On Public Equity Offering | |||||
| Subsequent Events | |||||
| Number of common stock issued | 5,000,000 | ||||
| Proceeds from Issuance of Common Stock | $ 100,000 | ||||
| Subsequent event | InnoCare Pharma Inc | |||||
| Subsequent Events | |||||
| Regulatory milestones payable | $ 20,000 | ||||
| Subsequent event | Convertible Debt | |||||
| Subsequent Events | |||||
| Aggregate amount of loan funded | $ 30,000 | ||||
| Payments of debt issuance costs | $ 900 | ||||
| Subsequent event | Follow On Public Equity Offering | |||||
| Subsequent Events | |||||
| Number of common stock issued | 750,000 | ||||
| Common stock, Per share | $ 20 | ||||
| Proceeds from Issuance of Common Stock | $ 15,000 | ||||
| Commission costs | $ 900 | ||||